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Case report
A 51-year-old female with a previous history of  gastric 
and duodenal ulcers (with biopsy-proven Helicobacter pylori) 
presented in June 2010 with symptoms of  abdominal pain 
and chronic diarrhea. She had persistent symptoms after 
confirmed eradication of  H. pylori. Enteroscopy showed 
diffuse fissuring, with an overlying mosaic appearance in 
the fundus and proximal stomach. The duodenum and 
jejunum appeared atrophic, with scattered nonbleeding 
ulcers. Biopsies showed chronic inactive gastritis in the 
stomach and mild villous shortening in the duodenum and 
jejunum. Tests for H.pylori, CMV, and HSV were negative. 
A test of  the serum gastrin level was above 5000 pg/mL, an 
extremely elevated value. The patient was placed on high-
dose proton-pump inhibitor therapy, and a search for a 
suspected gastrinoma began with computed tomography 
(CT) of  the abdomen and pelvis. 
CT images were obtained during the delayed phase after 
IV contrast administration. Likely because images were not 
obtained during the arterial phase, a 3.4 x 3.0-cm ovoid 
lesion in the caudate lobe, later identified on contrast-
enhanced magnetic resonance imaging (MRI), was not ini-
tially seen on the CT. In retrospect, this lesion is more 
clearly seen on MRI and can be faintly seen on CT (Fig. 1).
 On the MRI, the mass is most conspicuous in the arte-
rial phase, where it demonstrates a hypervascular appear-
ance (Figs. 2A and 2B). No other enhancing lesions were 
seen. 
Somatostatin-receptor scintigraphy (Octreoscan) was 
performed to look for additional tumor foci. Octreotide is a 
somatostatin analogue that binds to somatostatin receptors 
that can be found in a gastrinoma. The sensitivity of  Oc-
treoscan for detecting a gastrinoma depends highly on the 
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Figure 1. 51-year-old female with primary intrahepatic gas-
trinoma. Delayed, contrast-enhanced axial CT shows a 
subtle mass (red asterisk) in the caudate lobe that is 
isodense to the liver parenchyma with possible faint rim 
enhancement.
size of  the tumor, with a 30% sensitivity for tumors smaller 
than 1.1 cm but 96% for tumors larger than 2.0 cm (1). 
The Octreoscan showed a focal area of  intense uptake in 
the upper abdomen, almost in the midline, corresponding 
to the solid lesion seen on the MRI. (Fig. 3). No other areas 
of  increased radiotracer uptake were seen. 
Since no lesions outside the caudate lobe were identified 
on CT, MRI, or Octreoscan, the patient was referred for an 
intraoperative search for a possible primary lesion. The 
pancreas was thoroughly explored by opening the lesser sac 
to further visualize the head, neck, and body of  the pan-
creas. In addition, the gastrinoma triangle, hepatoduodenal 
ligament, and surrounding areas were explored. No mass 
was able to be visualized or palpated. The duodenum was 
carefully examined, and there was no evidence of  any ab-
normalities within the wall of  the duodenum. The duode-
num had previously been examined by endoscopic ultra-
sound without finding an abnormality. Open abdominal 
ultrasound was then carried out by the attending radiolo-
gist, and no extrahepatic gastrinoma was identified. After 
resection of  the caudate lesion, surgical pathology samples 
revealed a well-differentiated neuroendocrine carcinoma. 
The resection margins were negative for tumor (see pathol-
ogy images in Figs. 4A and 4B). Immunohistochemical 
stains for chromogranin and synaptophysin were positive, 
further indicative of  a neuroendocrine tumor. 
Following the patient’s tumor resection, she was seen in 
the gastroenterology clinic in order to monitor for signs of  
recurrence. It was initially feared that a small primary le-
sion in the duodenum or pancreas that was simply too 
small to be seen on imaging or intraoperatively had been 
missed, or that not all tumor had been resected. Therefore, 
the patient had serial secretin-stimulation tests (SST) per-
formed. This test can be used to differentiate patients with 
gastrinomas from those with the many other causes of  in-
creased serum gastrin. Secretin stimulates the release of  
gastrin by gastrinoma tumor cells; thus, patients with these 
tumors show a rise in serum gastrin in response to a secre-
tin administration. However, normal gastric G cells are 
inhibited by secretin, and therefore serum gastrin levels do 
not rise in patients with other causes of  hypergastrinemia 
(2). 
The SST is usually performed by administering 0.4 mcg 
of  secretin per kg body weight intravenously over a minute. 
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Figure 2. 51-year-old female with primary intrahepatic gas-
trinoma. T1 images, before (A) and after (B) gadolinium 
enhancement, show an oval, solid lesion within the caudate 
lobe of the liver measuring 3.4 x 3.0 cm (red asterisk). The 
lesion is most conspicuous on arterial dominant-phase-
enhanced images, where it demonstrates a hypervascular 
appearance. 
Figure 3. 51-year-old female with primary intrahepatic gas-
trinoma. Focal area of intense uptake in the upper abdo-
men almost in the midline (red arrow) corresponds to the 
solid lesion seen on the MRI. No other areas of increased 
uptake are seen.
Baseline serum gastrin is measured before the secretin is 
administered and at 2, 5, 10, 15, and 30 minutes later. One 
large study performed at the National Institutes of  Health 
(NIH) concluded that the optimal cutoff  for a positive SST 
was a rise of  ≥120 pg/mL in serum gastrin, which was 
associated with the highest sensitivity and specificity (94% 
and 100%, respectively) for detecting a gastrinoma (3). 
Although our patient did have a slight rise in gastrin con-
centrations from one month to six months following resec-
tion, both tests were negative using the standard set by the 
NIH trial, with only a 77 pg/mL rise in serum gastrin con-
centration following secretin administration at 6 months 
following surgery. The patient will require continued fol-
lowup, but so far she remains negative for residual or recur-
rent gastrinoma. 
Discussion
Zollinger-Ellison Syndrome (ZES), a disorder marked by 
severe peptic-ulcer disease and diarrhea, is caused by the 
hypersecretion of  gastric acid in response to a gastrin-
producing endocrine tumor. ZES typically affects patients 
who are between the ages of  35 to 65, with men being 
more frequently affected, by a 3:2 ratio. Approximately 
20% of  patients with ZES have multiple endocrine neopla-
sia (MEN) type 1, which is characterized by pancreatic en-
docrine tumors, pituitary adenomas, and parathyroid hy-
perplasia. Therefore, a diagnosis of  ZES should raise the 
suspicion of  these other entities. 
The clinical presentation of  ZES can be similar to 
peptic-ulcer disease from other causes, but symptoms that 
do not respond well to medical therapy with proton-pump 
inhibitors or H. pylori eradication should be viewed as suspi-
cious for ZES. When ZES is suspected, a fasting serum gas-
trin level is usually ordered, and a level above 1000 pg/mL 
is almost diagnostic of  a gastrinoma. However, other causes 
can result in elevated serum gastrin, including the use of  
proton-pump inhibitors. When the diagnosis remains in 
doubt, a SST can be performed, as outlined above. 
Once gastrinoma is clinically suspected, imaging should 
be performed to localize the tumor. On CT, a gastrinoma 
appears as a hypervascular mass that may demonstrate 
cystic areas with or without necrosis and calcifications. 
MRI also demonstrates a hypervascular mass that is T1-
hypointense and T2-hyperintense. These imaging findings 
are characteristic of  gastrinomas regardless of  where the 
tumor arises. Octreoscan is more specific for gastrinoma 
than CT or MRI, but with the aforementioned size 
limitations. 
Since 60% of  gastrinomas turn out to be malignant, 
surgical resection of  the primary tumor is recommended if  
there is no evidence for hepatic metastasis. Regardless of  
any evidence for metastatic disease, patients with ZES need 
medical therapy with high-dose proton-pump inhibitors to 
treat their symptoms related to acid hypersecretion (4).
Gastrinomas arise from amine-precursor uptake and 
decarboxylation (APUD) cells, which are multipotent, 
primitive neuroendocrine cells found in the central and 
peripheral nervous system, pulmonary mucosa, and gastro-
intestinal tract (5). In a gastrinoma, APUD cells undergo 
inappropriate differentiation to form G cells that produce 
gastrin. These cells are normally found in the gastric an-
trum. Gastrinomas are frequently found outside this loca-
tion, and when this occurs they are called ectopic. The 
common locations for ectopic gastrinomas are in the duo-
denum and pancreas, with over 85% of  primary gastrino-
mas being found in these locations. Neuroendocrine cells 
can also be found in bile ducts, which explains the rare 
occurrence of  intrahepatic gastrinomas (6). 
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Figure 4. 51-year-old female with primary intrahepatic gastrinoma. A. Low-magnification view (4X) of the resected caudate 
lobe lesion demonstrates a pseudoglandular pattern of growth, one of the typical patterns for neuroendocrine tumors. B. High-
magnification (40X) view of the lesion shows that the cell population is uniform, with finely granular, eosinophilic cytoplasm 
containing a low nuclear-to-cytoplasmic ratio. The nuclei are oval, with a dispersed chromatin ("salt and pepper") pattern.
Metastatic hepatic gastrinomas are much more common 
than primary lesions, but it is important to differentiate 
between these two entities because of  the worse prognosis 
associated with a metastasis. Patients with a metastatic gas-
trinoma lesion in the liver were found to have a decreased 
overall survival in one study (7). In contrast, patients with a 
resected primary lesion in any location that remained 
disease-free at 6 months (as our patient currently is) as de-
fined by a negative SST were found to have an 88% prob-
ability of  being disease-free at 3 years post resection (8). It is  
important for the radiologist to know the pathogenesis of  
these tumors, and to know that a gastrinoma may arise 
primarily at all locations where APUD cells are found. Also,  
because of  the prognostic implications, it is important to 
identify all foci of  tumor with gastrinomas when possible to 
direct the patient to the appropriate course of  treatment. 
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